Cramer welcomed Jonah Shackman, chairman and CEO of Medicis Pharmaceutical (MRX) to the show to discuss his company’s prospects. Shackman explained that his company’s LipoSonix product uses ultrasound to break up fat in the body so it can extracted naturally. The product is non-invasive, takes 45 minutes and reduces the waistline by several inches. Shackman said the product has been approved in Europe and he thinks it will be approved in the U.S. by 2011. However, Wall Street isn’t so thrilled with the product and many analysts think it won’t pass the Food and Drug Administration (FDA). “It’s easier to be negative than positive right now. LipoSonix is already selling well in Europe and Asia, and the company sees a very clear path to FDA approval in the United States,” he said. Cramer wouldn’t say if he would buy or sell the stock. But he did say the Wall Street’s pessimism around the possibility of the product’s approval is small-minded. Cramer advised investors to do their own due diligence on the company before making a decision. Get the scoop on tomorrow’s hottest trade ideas – TODAY! BeaconEquity.com PREMIER PICKS have an amazing track record. Join this select group and ride the profit wave!